Literature DB >> 7528614

Surgical results of penetrating keratoplasty in essential iris atrophy.

B M DeBroff1, R A Thoft.   

Abstract

BACKGROUND: Results of penetrating keratoplasty in iridocorneal endothelial syndrome have been considered favorable based on past studies; however, documented results in eyes specifically with essential iris atrophy are lacking.
METHODS: A retrospective study was performed to evaluate all patients at the University of Pittsburgh with essential iris atrophy who had undergone penetrating keratoplasty for corneal decompensation over 21 years (1971-1992).
RESULTS: Penetrating keratoplasty had been performed on six eyes with essential iris atrophy for corneal decompensation. All eyes postoperatively had evidence of persistent anterior uveitis resistant to corticosteroid treatment with one or more episodes of graft reaction. Five of the six eyes (83.3%) ultimately went on to graft failure. Two of the six eyes (33.3%) rejected grafts on two separate occasions.
CONCLUSIONS: Penetrating keratoplasty in essential iris atrophy was frequently associated with chronic anterior uveitis and immunologic graft failure.

Entities:  

Mesh:

Year:  1994        PMID: 7528614

Source DB:  PubMed          Journal:  J Refract Corneal Surg        ISSN: 1081-0803


  3 in total

1.  Clinical outcome of Descemet stripping automated endothelial keratoplasty in 18 cases with iridocorneal endothelial syndrome.

Authors:  M Ao; Y Feng; G Xiao; Y Xu; J Hong
Journal:  Eye (Lond)       Date:  2017-12-15       Impact factor: 3.775

Review 2.  Diagnosis and Management of Iridocorneal Endothelial Syndrome.

Authors:  Marta Sacchetti; Flavio Mantelli; Marco Marenco; Ilaria Macchi; Oriella Ambrosio; Paolo Rama
Journal:  Biomed Res Int       Date:  2015-09-16       Impact factor: 3.411

3.  Iridocorneal endothelial syndrome in a patient with keratoconus - a case report.

Authors:  Michele De Maria; Danilo Iannetta; Antonio Moramarco; Luigi Fontana
Journal:  BMC Ophthalmol       Date:  2019-11-11       Impact factor: 2.209

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.